Get In Touch
541 Melville Ave, Palo Alto, CA 94301,
ask@ohio.colabr.io
Ph: +1.831.705.5448
Work Inquiries
work@ohio.colabr.io
Ph: +1.831.306.6725

Invest in the Future of Prostate Health

An Innovative medtech device designed to improve prostate health management

*See Legal Disclaimer at the bottom of the page.

“We are leading the development of a new paradigm that transforms the diagnosis, treatment, screening, monitoring, and management of prostate care early, with the patient’s journey in mind. The unmet medical need addressed by the ProstaMetrix device is assisting in distinguishing aggressive from indolent prostate cancer.”

– Christopher G. LaFarge, Chief Operating Officer

The Current Problem

The existing problem with Prostate Health Management

In the United States, prostate cancer is the second most common cancer in men, second only to skin cancer. Distinguishing between indolent and aggressive cancer is difficult, often leading to overtreatment of indolent cancers and delayed treatments for those with aggressive types.

One in eight men will be diagnosed with prostate cancer, over 33,330 will die in the US alone

Prostate cancer is the second leading cause of cancer death in men in the US

Today, there is no cost-effective and non-invasive way to distinguish between aggressive and indolent prostate cancer

*See Legal Disclaimer at the bottom of the page.

The Solution

The ProstaMetrixTM System

ProstaMetrix is a portable, physician’s office medical tech device that turns a digital rectal exam into a next generation cancer screening tool. The ProstaMetrix device makes it possible to treat multiple forms of prostate disorder and diseases in a low-cost, point-of-care and real-time procedure.

How it Works

  • Encoder is placed over fingertip during a routing digital rectalexam (DRE).
  • Fiber optic sensors coupled with patented technology measures prostate width and accurately calculates crucial prostate volume.
  • Prostate volume measurements are delivered on screen in real-time.

The Benefits of
ProstaMetrixTM

Less invasive diagnostic option for patients
Less invasive diagnostic option for patients

An efficient way for patients and physicians to monitor the progression of the disease
An efficient way for patients and physicians to monitor the progression of the disease

Lower costs of diagnosis for patients
Lower costs of diagnosis for patients

Increased speed in diagnostic information available for physicians
Increased speed in diagnostic information available for physicians

Reduction of over-treatment of indolent cancer, which exceeds $3.0 billion annually in the United States
Reduction of over-treatment of indolent cancer, which exceeds $3.0 billion annually in the United States

Two senior healthcare workers in consultation laughing

Market Opportunity

Through the development of ProstaMetrix, MedicaMetrix is well-positioned to provide value to investors in a growth industry.

  • Medical device industry valued at $456.9 billion in 2020, and is increasing at a compounded annual growth rate (CAGR) of 6.1%
  • Prostate Cancer Diagnostics market valued at $3.32 billion in 2020 and expected to reach $7.65 billion by 2027 for CAGR of 13.2%

MedicaMetrix Growth Track

Traction

MedicaMetrix has developed and manufactured a revolutionary prostate screening device, ProstaMetrix, which has been certified for use in the Eurozone, UK, and India.

2020

Complete Develop & Conduct UK Clinicals

  • Complete development and manufacturing scale-up of the current version of the ProstaMetrix device
  • Conduct clinical and economic assessment trials using of the device in the UK
  • Begin recruitment of “early adopter” urologists in the UK

Jan-Jun

2021

UK Market Launch & EU Clinicals

  • Limited market release of product to the 10 clinical study markets in the UK
  • Identify and expand to 15-20 additional UK metro markets
  • Begin recruitment of “early adopter” urologists in the US, DE, NL, BE and SE
  • Begin recruitment of “early adopter” urologists in the US, DE, NL, BE and SE
  • Conduct small clinical market trials in DE, NL, BE and SE

Jul-Dec

2021

EU Market Launch & Global Distribution

  • Initiate limited market release in selected metro markets in the US, Netherlands, Germany and Sweden
  • Conduct clinical and economic assessment trials using of the device in the UK
  • Pursue global distribution partner to sell and support the product in North America, UK, EU and Nordic regions

*See Legal Disclaimer at the bottom of the page.

Leadership Team

MedicaMetrix has a proven leadership team with years of experience creating successful new companies, launching new medical products and technologies, and creating value for early-stage to global 100 companies.

Satish Vankayalapati

Chairman

Robert Rudelius

President and Chief Executive Officer

Christopher G. Lafarge

Chief Operating Officer

Richard C. Carlson

Executive VP Business Development

Peter Madras

M.D. Director, Clinical Research

John A. Libertino

M.D., Medical Advisor

Download our Investor Deck

Name(Required)
Consent(Required)
This field is for validation purposes and should be left unchanged.

News & Press Releases

MedicaMetrix Announces FDA Registration of MedicaMetrix Devices Private Limited for Manufacturing Purposes

This registration for the company’s manufacturing division in India prepares for future…

MedicaMetrix Completes Conversion to Corporation

MedicaMetrix’s conversion to a C-Corp positions the company for long-term value creation…

Top